We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly's 2025 Surge Sets the Stage for Another Big Year in 2026
Read MoreHide Full Article
Key Takeaways
LLY delivered $65.2B in 2025 revenues, up 45%, with EPS rising 86% to $24.21.
Mounjaro and Zepbound generated $36.5B in 2025, about 56% of LLY's total revenues.
LLY sees 2026 revenues of $80-$83B and EPS of $33.50-$35.00, with higher R&D and SG&A.
Eli Lilly and Company (LLY - Free Report) announced fourth-quarter and full-year results last week. The company delivered robust financial performance in 2025 with revenues of $65.2 billion rising 45% and EPS growing 86% to $24.21. Revenue growth was driven by the robust uptake of Lilly’s popular GLP-1 drugs, Mounjaro for type II diabetes and Zepbound for obesity. In 2025, the drugs generated combined sales of $36.5 billion, comprising around 56% of the company’s total revenues.
Lilly’s other new products, like Ebglyss, Inluriyo, Jaypirca, Kisunla and Omvoh, also contributed to sales growth.
Along with its earnings results, Lilly also announced a bullish outlook for 2026. In 2026, Lilly expects to record revenues in the range of $80 billion to $83 billion, representing an increase of 25% at the midpoint. Earnings per share are expected to be in the range of $33.50 to $35.00, representing growth of more than 40% at the midpoint.
Lilly expects continued robust growth of Mounjaro and Zepbound in 2026, backed by continued strong demand trends. While newer drugs like Ebglyss, Jaypirca, Inluriyo, Kisunla and Omvoh are expected to contribute to growth in 2026, late-life cycle products like Trulicity, Taltz and Verzenio are expected to be flat or decline.
Sales of Trulicity are being hurt due to competitive dynamics, including patient switches to Mounjaro and lower realized prices, while soft demand trends in the United States are hurting Verzenio’s sales.
Adjusted gross margin is expected to be relatively stable to slightly down in 2026. R&D expenses are expected to increase in 2026 as the company expands its pipeline and plans to initiate more phase III studies in 2026. Marketing, selling and administrative expenses are also expected to rise in 2026.
Eli Lilly started 2026 on a strong footing after a standout 2025, powered by surging demand for Mounjaro and Zepbound. With revenues and earnings set to climb sharply, newer product launches gaining traction, and increased investment in R&D and commercialization, the company is positioning its growth engines even as some mature products face pressure.
Race to Make Oral Obesity Pill Intensifies
Competition in the obesity market is heating up. Mounjaro and Zepbound face strong competition from Novo Nordisk’s (NVO - Free Report) semaglutide medicines, Ozempic for diabetes and Wegovy for obesity.
Novo Nordisk gained approval for an oral version of Wegovy in December 2025 and launched the pill in January 2026. Wegovy is the first oral GLP-1 drug to be approved in the United States, ushering in a new era of obesity treatment. The Wegovy pill gives NVO the first-to-market advantage and will initially bring in additional revenues, which may hurt Lilly’s market share. However, we believe Lilly may be able to close the gap fast, once its own oral GLP-1 obesity pill, orforglipron is approved by the FDA in 2026.
Smaller biotechs like Structure Therapeutics (GPCR - Free Report) and Viking Therapeutics (VKTX - Free Report) are also developing oral GLP-1 drugs for treating obesity.
LLY’s Stock Price, Valuation and Estimates
Lilly’s stock has risen 20.7% in the past year compared with the industry’s increase of 17.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, Lilly’s stock is expensive. Going by the price/earnings ratio, LLY’s shares currently trade at 30.52 forward earnings, much higher than 18.76 for the industry. However, LLY’s stock is trading below its 5-year mean of 34.57.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 has risen from $33.14 per share to $33.28 per share over the past 30 days, while that for 2027 has risen from $41.53 to $41.72 per share over the same timeframe.
View the Zacks #1 Rank List
Image: Bigstock
Eli Lilly's 2025 Surge Sets the Stage for Another Big Year in 2026
Key Takeaways
Eli Lilly and Company (LLY - Free Report) announced fourth-quarter and full-year results last week. The company delivered robust financial performance in 2025 with revenues of $65.2 billion rising 45% and EPS growing 86% to $24.21. Revenue growth was driven by the robust uptake of Lilly’s popular GLP-1 drugs, Mounjaro for type II diabetes and Zepbound for obesity. In 2025, the drugs generated combined sales of $36.5 billion, comprising around 56% of the company’s total revenues.
Lilly’s other new products, like Ebglyss, Inluriyo, Jaypirca, Kisunla and Omvoh, also contributed to sales growth.
Along with its earnings results, Lilly also announced a bullish outlook for 2026. In 2026, Lilly expects to record revenues in the range of $80 billion to $83 billion, representing an increase of 25% at the midpoint. Earnings per share are expected to be in the range of $33.50 to $35.00, representing growth of more than 40% at the midpoint.
Lilly expects continued robust growth of Mounjaro and Zepbound in 2026, backed by continued strong demand trends. While newer drugs like Ebglyss, Jaypirca, Inluriyo, Kisunla and Omvoh are expected to contribute to growth in 2026, late-life cycle products like Trulicity, Taltz and Verzenio are expected to be flat or decline.
Sales of Trulicity are being hurt due to competitive dynamics, including patient switches to Mounjaro and lower realized prices, while soft demand trends in the United States are hurting Verzenio’s sales.
Adjusted gross margin is expected to be relatively stable to slightly down in 2026. R&D expenses are expected to increase in 2026 as the company expands its pipeline and plans to initiate more phase III studies in 2026. Marketing, selling and administrative expenses are also expected to rise in 2026.
Eli Lilly started 2026 on a strong footing after a standout 2025, powered by surging demand for Mounjaro and Zepbound. With revenues and earnings set to climb sharply, newer product launches gaining traction, and increased investment in R&D and commercialization, the company is positioning its growth engines even as some mature products face pressure.
Race to Make Oral Obesity Pill Intensifies
Competition in the obesity market is heating up. Mounjaro and Zepbound face strong competition from Novo Nordisk’s (NVO - Free Report) semaglutide medicines, Ozempic for diabetes and Wegovy for obesity.
Novo Nordisk gained approval for an oral version of Wegovy in December 2025 and launched the pill in January 2026. Wegovy is the first oral GLP-1 drug to be approved in the United States, ushering in a new era of obesity treatment. The Wegovy pill gives NVO the first-to-market advantage and will initially bring in additional revenues, which may hurt Lilly’s market share. However, we believe Lilly may be able to close the gap fast, once its own oral GLP-1 obesity pill, orforglipron is approved by the FDA in 2026.
Smaller biotechs like Structure Therapeutics (GPCR - Free Report) and Viking Therapeutics (VKTX - Free Report) are also developing oral GLP-1 drugs for treating obesity.
LLY’s Stock Price, Valuation and Estimates
Lilly’s stock has risen 20.7% in the past year compared with the industry’s increase of 17.7%.
From a valuation standpoint, Lilly’s stock is expensive. Going by the price/earnings ratio, LLY’s shares currently trade at 30.52 forward earnings, much higher than 18.76 for the industry. However, LLY’s stock is trading below its 5-year mean of 34.57.
The Zacks Consensus Estimate for 2026 has risen from $33.14 per share to $33.28 per share over the past 30 days, while that for 2027 has risen from $41.53 to $41.72 per share over the same timeframe.
LLY’s Zacks Rank
Lilly has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.